1. The five dopamine receptors are sorted into two families by their G protein coupling and downstream effect on cyclic AMP. Which receptor belongs to the family that couples to inhibitory Gi/Go proteins and reduces cyclic AMP?
A) D1
B) D5
C) D1 and D5 only
D) D2
E) None of the dopamine receptors lower cyclic AMP
ANSWER: D
Rationale:
The D2-like family (D2, D3, and D4) couples to inhibitory Gi/Go proteins and lowers cyclic AMP, whereas the D1-like family (D1 and D5) couples to stimulatory Gs and raises cyclic AMP. Of the options listed, D2 is the only one that belongs to the cAMP-lowering family, making it the correct answer. Precise assignment of each receptor to the correct family is foundational, because the opposing signaling directions of the two families underlie their divergent effects on the circuits relevant to psychosis.
Option A: Option A is incorrect because D1 is a D1-like receptor that raises cyclic AMP.
Option B: Option B is incorrect because D5 is also a D1-like receptor coupled to Gs.
Option C: Option C is incorrect because it names the two D1-like receptors, which raise rather than lower cyclic AMP.
Option E: Option E is incorrect because the D2-like family does lower cyclic AMP through Gi/Go coupling.
2. A landmark 1970s observation provided strong mechanistic support for the dopamine hypothesis by relating a drug-binding property of first-generation antipsychotics to their clinical dosing. Across a range spanning roughly six orders of magnitude, what did the clinical potency of these agents correlate with most precisely?
A) Their affinity for the dopamine D2 receptor
B) Their affinity for the histamine H1 receptor
C) Their plasma elimination half-life
D) Their lipid solubility (logP)
E) Their affinity for the serotonin 2A receptor
ANSWER: A
Rationale:
The clinical potency of first-generation antipsychotics correlated almost precisely with their affinity for the D2 receptor across about six orders of magnitude of binding affinity — one of the most striking structure-activity relationships in clinical psychopharmacology. This is why a high-affinity agent such as haloperidol is effective at single-digit milligram doses while a lower-affinity agent such as chlorpromazine requires hundreds of milligrams.
Option B: Option B is incorrect because H1 affinity tracks sedation and weight gain, not antipsychotic potency.
Option C: Option C is incorrect because half-life governs dosing interval, not the milligram potency relationship.
Option D: Option D is incorrect because lipid solubility affects distribution and onset but does not define the potency correlation.
Option E: Option E is incorrect because 5-HT2A affinity is a feature of later second-generation agents and was not the basis of this first-generation potency correlation.
3. Precise knowledge of where each dopaminergic pathway originates is needed to predict the effects of D2 blockade. Which of the following correctly matches a pathway to its nucleus of origin?
A) The mesolimbic pathway originates in the substantia nigra pars compacta
B) The tuberoinfundibular pathway originates in the ventral tegmental area
C) The nigrostriatal pathway originates in the substantia nigra pars compacta
D) The mesocortical pathway originates in the hypothalamic arcuate nucleus
E) The nigrostriatal pathway originates in the ventral tegmental area
ANSWER: C
Rationale:
The nigrostriatal pathway originates in the substantia nigra pars compacta and projects to the dorsal striatum, which is why its blockade produces extrapyramidal motor effects and why its degeneration causes Parkinson disease. The other origins are: mesolimbic and mesocortical both from the ventral tegmental area, and tuberoinfundibular from the hypothalamic arcuate nucleus.
Option A: Option A is incorrect because the mesolimbic pathway arises from the ventral tegmental area, not the substantia nigra.
Option B: Option B is incorrect because the tuberoinfundibular pathway arises from the hypothalamic arcuate nucleus, not the ventral tegmental area.
Option D: Option D is incorrect because the mesocortical pathway arises from the ventral tegmental area, not the arcuate nucleus.
Option E: Option E is incorrect because it assigns the nigrostriatal pathway to the ventral tegmental area rather than to the substantia nigra pars compacta.
4. Among the D2-like receptors, one subtype is concentrated in limbic regions such as the nucleus accumbens shell and olfactory tubercle, with relatively limited expression in the dorsal striatum — a distribution that makes it an attractive target for modulating reward and motivation with reduced motor side-effect risk. Which receptor subtype has this predominantly limbic distribution?
A) D1
B) D3
C) D5
D) D2
E) D4
ANSWER: B
Rationale:
The D3 receptor is concentrated in limbic regions — particularly the nucleus accumbens shell and olfactory tubercle — with comparatively limited dorsal striatal expression. This limbic predominance is the rationale behind agents such as cariprazine, a partial agonist with preferential D3 over D2 affinity, used to target negative symptoms and motivational deficits with lower motor risk.
Option A: Option A is incorrect because D1 is a D1-like receptor most densely expressed in the striatum and prefrontal cortex.
Option C: Option C is incorrect because D5 is a D1-like receptor distributed in regions such as the hippocampus and hypothalamus.
Option D: Option D is incorrect because D2 is expressed at high density in the dorsal striatum, the opposite of the limited striatal pattern described.
Option E: Option E is incorrect because D4 is expressed at low overall density, concentrated in frontal cortex, amygdala, hippocampus, and midbrain rather than showing this nucleus accumbens shell predominance.
5. The revised ("updated") dopamine hypothesis that emerged from neuroimaging studies is more anatomically specific than the original. Which statement best captures its central claim about regional dopamine activity in schizophrenia?
A) Dopamine activity is uniformly elevated throughout the entire brain
B) Dopamine activity is uniformly reduced throughout the entire brain
C) The mesocortical pathway is hyperdopaminergic while the mesolimbic pathway is hypodopaminergic
D) Dopamine activity is normal, and the illness is driven entirely by serotonin
E) The mesolimbic pathway is hyperdopaminergic while the mesocortical pathway is hypodopaminergic
ANSWER: E
Rationale:
The updated hypothesis holds that schizophrenia involves concurrent mesolimbic hyperdopaminergia — driving positive symptoms such as hallucinations and delusions — alongside mesocortical hypodopaminergia, which underlies negative symptoms and cognitive deficits. This anatomically differentiated model explains why nonselective D2 blockade can suppress positive symptoms while leaving negative symptoms unimproved or worsened. Option A restates the original, anatomically nonspecific hypothesis that the revised model superseded.
Option B: Option B is incorrect because mesolimbic activity is elevated, not globally reduced.
Option C: Option C inverts the model by reversing the two pathways.
Option D: Option D is incorrect because the revised hypothesis retains dopamine dysregulation as central, with glutamate proposed as an upstream contributor rather than a sole driver.
6. Negative symptoms in schizophrenia are classified as primary or secondary, a distinction with direct treatment consequences. Which statement correctly characterizes this distinction?
A) Primary negative symptoms arise from extrapyramidal akinesia and resolve when the dose is lowered
B) Secondary negative symptoms are intrinsic to the illness and respond poorly to all current treatments
C) Primary and secondary negative symptoms are clinically identical and cannot be distinguished
D) Primary negative symptoms are intrinsic to the illness; secondary ones arise from identifiable, often remediable causes
E) Secondary negative symptoms reflect the mesocortical dopamine deficit and are irreversible
ANSWER: D
Rationale:
Primary negative symptoms are intrinsic to the illness itself and reflect the underlying mesocortical dopamine deficit, whereas secondary negative symptoms arise from identifiable and often remediable causes — extrapyramidal akinesia mimicking avolition and blunted affect, depression, social withdrawal driven by positive symptoms, or medication-induced sedation. The distinction matters because secondary symptoms can improve once their cause is addressed, while primary symptoms require strategies aimed at the underlying deficit.
Option A: Option A is incorrect because akinesia-driven, dose-reversible symptoms are secondary, not primary.
Option B: Option B is incorrect because it attaches the "intrinsic" label to secondary symptoms.
Option C: Option C is incorrect because the two are distinguishable precisely by whether an identifiable remediable cause is present.
Option E: Option E is incorrect because it assigns the mesocortical deficit and irreversibility to the secondary category, reversing the correct attribution.
7. PET occupancy studies defined a therapeutic window for striatal D2 receptor occupancy and a threshold above which side effects rise sharply. Which pair of values correctly states the antipsychotic response range and the extrapyramidal-symptom threshold?
A) Response correlates with occupancy of about 65 to 80 percent; extrapyramidal symptoms rise steeply above about 80 percent
B) Response requires about 20 to 40 percent occupancy; extrapyramidal symptoms appear above about 50 percent
C) Response requires about 90 to 100 percent occupancy; extrapyramidal symptoms are unrelated to occupancy
D) Response correlates with about 65 to 80 percent occupancy; extrapyramidal symptoms appear only above about 95 percent
E) Response requires about 40 to 60 percent occupancy; extrapyramidal symptoms rise steeply above about 65 percent
ANSWER: A
Rationale:
Antipsychotic response correlates with striatal D2 occupancy in the range of about 65 to 80 percent, and occupancy above roughly 80 percent is associated with a steep rise in extrapyramidal symptoms without additional antipsychotic benefit. This window is the quantitative basis for why dose escalation beyond the recommended range adds toxicity rather than efficacy. Option E sets both the response range and the extrapyramidal threshold too low relative to the established values.
Option B: Option B understates both values; occupancy in the 20 to 40 percent range is generally subtherapeutic.
Option C: Option C is incorrect because effective response does not require near-complete occupancy and extrapyramidal risk is clearly occupancy-dependent.
Option D: Option D states the correct response range but misplaces the extrapyramidal threshold far too high at about 95 percent.
8. The dopamine hypothesis alone does not fully account for schizophrenia, and a complementary model invokes glutamate. Which observation is the principal evidence cited for the glutamatergic (NMDA-receptor hypofunction) contribution?
A) Amphetamine reproduces the full schizophrenia syndrome, including negative and cognitive symptoms
B) Selective serotonin reuptake inhibitors reliably induce a psychotic state in healthy volunteers
C) NMDA-receptor antagonists such as phencyclidine and ketamine reproduce positive, negative, and cognitive symptoms more completely than amphetamine
D) Dopamine-depleting agents such as reserpine reproduce the full syndrome
E) GABA-receptor agonists reproduce the negative symptoms of schizophrenia
ANSWER: C
Rationale:
The N-methyl-D-aspartate (NMDA) receptor antagonists phencyclidine and ketamine reproduce a syndrome resembling schizophrenia more completely than amphetamine — adding negative symptoms and cognitive disorganization to the positive symptoms — which is the principal evidence for an NMDA-receptor hypofunction contribution. The model proposes that NMDA hypofunction on cortical inhibitory interneurons disinhibits downstream dopamine neurons, linking the glutamate and dopamine accounts.
Option A: Option A is incorrect because amphetamine reproduces mainly positive symptoms, not the full syndrome — the very limitation the glutamate model addresses.
Option B: Option B is incorrect because serotonin reuptake inhibitors do not reliably induce psychosis.
Option D: Option D is incorrect because reserpine depletes dopamine and reduces psychotic symptoms rather than reproducing the syndrome.
Option E: Option E is incorrect because GABA-receptor agonists are sedating and are not the basis of the glutamatergic model.
9. Antipsychotics bind several receptors beyond D2, and each off-target action maps to a characteristic adverse effect. Which receptor-to-effect pairing is correct?
A) Muscarinic M1 blockade — orthostatic hypotension
B) Histamine H1 blockade — sedation and weight gain
C) Alpha-1 adrenergic blockade — dry mouth and urinary retention
Histamine H1 blockade is the primary mechanism of antipsychotic sedation and contributes substantially to weight gain, making this the correct pairing. The other adverse effects map to distinct receptors: orthostatic hypotension to alpha-1 blockade, anticholinergic effects (dry mouth, urinary retention) to muscarinic M1 blockade, and QTc prolongation to cardiac hERG potassium-channel blockade.
Option A: Option A is incorrect because orthostatic hypotension arises from alpha-1, not M1, blockade.
Option C: Option C is incorrect because dry mouth and urinary retention are anticholinergic effects of M1, not alpha-1, blockade.
Option D: Option D is incorrect because QTc prolongation reflects hERG channel blockade rather than 5-HT2A blockade.
Option E: Option E is incorrect because extrapyramidal symptoms result from nigrostriatal D2 blockade, not from H1 blockade.
10. A single binding-affinity relationship is the most commonly cited mechanistic predictor distinguishing the lower extrapyramidal liability of second-generation agents from first-generation agents. Which relationship is it?
A) A high D2-to-H1 affinity ratio
B) A high alpha-1-to-D2 affinity ratio
C) A high M1-to-D2 affinity ratio
D) A high 5-HT2A-to-D2 affinity ratio
E) A high D3-to-D4 affinity ratio
ANSWER: D
Rationale:
A relatively high ratio of serotonin 2A (5-HT2A) to D2 binding affinity is the property most often cited to distinguish second-generation from first-generation agents and is a reasonable, though imperfect, predictor of extrapyramidal liability across agents. The mechanism is that cortical and striatal 5-HT2A blockade disinhibits dopamine release, partially offsetting D2 blockade and raising the extrapyramidal threshold.
Option A: Option A is incorrect because the D2-to-H1 ratio relates to sedation, not the extrapyramidal-sparing distinction.
Option B: Option B is incorrect because the alpha-1-to-D2 ratio tracks orthostatic effects.
Option C: Option C is incorrect because the M1-to-D2 ratio relates to anticholinergic burden.
Option E: Option E is incorrect because the D3-to-D4 ratio is not the established predictor of class-level extrapyramidal liability.
11. A clinically important difference between the tuberoinfundibular and nigrostriatal pathways concerns how they behave over time during continued D2 blockade. Which statement correctly captures this difference?
A) Both pathways develop complete tolerance, so neither prolactin elevation nor extrapyramidal symptoms persist
B) The nigrostriatal pathway shows no tolerance, so extrapyramidal symptoms always worsen indefinitely
C) The tuberoinfundibular pathway rapidly develops full tolerance, so hyperprolactinemia resolves within days
D) Neither pathway is affected by continued D2 blockade after the first dose
E) The tuberoinfundibular pathway does not develop tolerance the way the nigrostriatal system partially does, so hyperprolactinemia tends to persist
ANSWER: E
Rationale:
Unlike the nigrostriatal system, which partially adapts to D2 blockade over time, the tuberoinfundibular pathway does not develop comparable tolerance, so antipsychotic-induced hyperprolactinemia tends to persist as a chronic effect rather than attenuating with continued treatment. This is why prolactin-related effects often require active management rather than simply waiting them out.
Option A: Option A is incorrect because the tuberoinfundibular pathway does not develop tolerance and prolactin elevation persists.
Option B: Option B overstates the nigrostriatal behavior; it shows partial, not absent, tolerance, and extrapyramidal symptoms do not invariably worsen indefinitely.
Option C: Option C is incorrect because hyperprolactinemia does not resolve within days through tolerance.
Option D: Option D is incorrect because continued D2 blockade clearly produces ongoing effects in both pathways.
12. Clozapine, the prototypical atypical antipsychotic, has a receptor profile that distinguishes it from most other agents in the class. Which description best characterizes its pharmacology?
A) Relatively modest D2 affinity combined with high affinity at multiple other receptors, including D4, 5-HT2A, H1, M1, and alpha-1
B) The highest D2 affinity of any antipsychotic, with negligible activity at other receptors
C) Pure, selective D2 antagonism with no meaningful action elsewhere
D) Partial D2 agonism as its single defining mechanism, like aripiprazole
E) Selective 5-HT2A antagonism with no dopaminergic activity at all
ANSWER: A
Rationale:
Clozapine is a multi-receptor agent with relatively modest D2 affinity but high affinity at numerous other receptors, including D4, D1, 5-HT2A, H1, M1, and alpha-1 — a broad profile that distinguishes it from most other antipsychotics and accompanies its status as the agent with the strongest evidence in treatment-resistant schizophrenia.
Option B: Option B is incorrect because clozapine's D2 affinity is comparatively modest, not the highest, and it is far from inactive elsewhere.
Option C: Option C is incorrect because clozapine is the opposite of a selective D2 antagonist.
Option D: Option D describes aripiprazole's partial-agonist mechanism, which is not clozapine's defining feature.
Option E: Option E is incorrect because clozapine retains D2 and broad dopaminergic activity rather than being a pure 5-HT2A antagonist.
13. The CATIE study compared a first-generation agent against several second-generation agents in a real-world population. What was its principal finding, and what was the main implication?
A) Every second-generation agent was dramatically superior on all-cause discontinuation, confirming categorical SGA superiority
B) The first-generation agent was withdrawn early for lack of any efficacy
C) Perphenazine performed comparably to the second-generation agents on all-cause discontinuation, moderating the view that SGAs are categorically superior
D) The first-generation agent caused no extrapyramidal effects, eliminating any reason to prefer SGAs
E) All agents were identical on every metabolic and neurologic measure without exception
ANSWER: C
Rationale:
In CATIE, the mid-potency first-generation agent perphenazine performed comparably to several second-generation agents on the primary measure of all-cause discontinuation, a result that moderated early enthusiasm for treating second-generation agents as categorically superior to all first-generation drugs. The practical implication is that agent selection should be individualized rather than driven by a blanket class preference.
Option A: Option A overstates the result into a categorical SGA victory the trial did not show.
Option B: Option B is incorrect because the first-generation comparator was retained and performed comparably, not withdrawn for inefficacy.
Option D: Option D is incorrect because the finding concerned discontinuation rates, not an absence of extrapyramidal effects.
Option E: Option E overstates the comparability into identity on every measure, which the trial did not demonstrate.
14. In the prefrontal cortex, D1 receptor activation modulates the persistent neuronal firing that supports working memory, and the relationship between D1 stimulation and cognitive performance follows a particular shape. Which statement describes it correctly?
A) Performance rises linearly without limit as D1 stimulation increases
B) The relationship is an inverted U: both too little and too much D1 stimulation degrade working memory, with an optimum in between
C) D1 stimulation has no effect on working memory at any level
D) Only excessive D1 stimulation impairs working memory; low levels are always optimal
E) Working memory is best at the highest achievable level of D1 stimulation
ANSWER: B
Rationale:
The relationship between prefrontal D1 stimulation and working memory follows an inverted-U curve: at low dopamine input, D1 stimulation is insufficient to sustain the persistent firing that underlies working memory; at moderate levels it is optimal; and at high levels, excessive activation suppresses firing and degrades performance. This explains why both the hypodopaminergia of schizophrenia and high-dose stimulant excess impair cognition by sitting on opposite sides of the optimum.
Option A: Option A is incorrect because performance does not rise without limit; it falls past the optimum.
Option C: Option C is incorrect because D1 stimulation clearly modulates working memory.
Option D: Option D is incorrect because insufficient stimulation also impairs performance, so low levels are not always optimal.
Option E: Option E is incorrect because the highest level of stimulation degrades rather than maximizes working memory.
15. Two adverse-effect burdens are distributed differently across the antipsychotic classes. Which statement correctly assigns each burden to the class in which it predominates?
A) Metabolic effects predominate in high-potency first-generation agents; extrapyramidal symptoms predominate in second-generation agents
B) Both metabolic effects and extrapyramidal symptoms are essentially absent from all antipsychotics
C) Metabolic effects and extrapyramidal symptoms are equally distributed across every agent
D) Metabolic effects (weight gain, glucose dysregulation, dyslipidemia) predominate in second-generation agents, especially clozapine and olanzapine, while extrapyramidal symptoms predominate with high-potency first-generation agents
E) Extrapyramidal symptoms predominate in low-potency first-generation agents, while metabolic effects predominate in high-potency first-generation agents
ANSWER: D
Rationale:
The metabolic effects — weight gain, glucose dysregulation, and dyslipidemia — are concentrated in the second-generation class and are most pronounced with clozapine and olanzapine, whereas extrapyramidal symptoms predominate with high-potency first-generation agents owing to their tight D2 binding and limited offsetting receptor activity. Recognizing this split is central to individualized agent selection. Option E misassigns extrapyramidal predominance to low-potency agents and metabolic predominance to high-potency first-generation agents, both of which are incorrect.
Option A: Option A reverses both assignments.
Option B: Option B is incorrect because both burdens are clinically prominent in the relevant agents.
Option C: Option C is incorrect because the burdens are not uniformly distributed; each concentrates in a different class.
16. Treatment-resistant schizophrenia is a defined clinical category with a specific evidence-based pharmacological response. Which statement correctly pairs the defining feature with the agent of choice?
A) It is defined by prominent metabolic side effects, and the agent of choice is a high-potency first-generation drug
B) It is defined by early extrapyramidal symptoms, and the agent of choice is an anticholinergic
C) It is defined by elevated prolactin, and the agent of choice is a dopamine agonist
D) It is defined by intolerable sedation, and the agent of choice is a low-potency first-generation drug
E) It is defined by persistent positive symptoms despite adequate D2 occupancy across adequate trials, affecting roughly 20 to 30 percent of patients, and clozapine has the strongest evidence
ANSWER: E
Rationale:
Treatment-resistant schizophrenia is defined by persistent positive symptoms despite adequate D2 occupancy across adequate antipsychotic trials, a category applying to roughly 20 to 30 percent of patients, and clozapine has the strongest evidence base for it. Because positive symptoms are normally the most treatment-responsive dimension, their persistence after adequate blockade is precisely what marks resistance.
Option A: Option A is incorrect because resistance is defined by persistent psychosis, not metabolic effects, and a high-potency first-generation drug is not the evidence-based choice.
Option B: Option B is incorrect because extrapyramidal symptoms are a movement side effect, not the defining feature, and anticholinergics do not treat resistance.
Option C: Option C is incorrect because elevated prolactin is a hormonal effect, not the definition, and dopamine agonists would worsen psychosis.
Option D: Option D is incorrect because sedation does not define resistance, and a low-potency first-generation drug is not the agent of choice.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.